CXCR3缺失通过调节小鼠青光眼模型中的神经元-星形胶质细胞通讯减轻视网膜神经节细胞丢失
本研究重新分析公开的小鼠青光眼模型视网膜RNA测序数据,并在微珠诱导青光眼小鼠模型及原代RGC和星形胶质细胞中验证CXCL10/CXCR3轴的作用;结果显示CXCR3缺失可显著防止RGC丢失和轴突变性而不影响眼压,视觉功能得以保留,机制涉及星形胶质细胞C3和RGC C3aR上调,基因治疗或C3aR阻断可减少RGC丢失。
要点
- 微珠模型中CXCL10在注射后第5天明显升高,第6周时CXCR3缺失显著防止RGC丢失和轴突变性且不影响眼压。
- CXCR3缺失小鼠的图形视网膜电图和视力评估显示视觉功能得以保留。
- CXCL10/CXCR3信号上调星形胶质细胞C3和RGC C3aR,驱动毒性星形胶质细胞-RGC交互。
核心结论
- CXCL10/CXCR3信号是青光眼中RGC丢失的关键介质,靶向该通路及其上调的C3/C3aR轴是前景可期的非眼压依赖性治疗策略。
研究设计与样本
- 重新分析公开的小鼠青光眼模型视网膜bulk RNA测序数据集以鉴定差异表达的趋化因子。
- 使用微珠诱导青光眼小鼠模型及原代RGC和星形胶质细胞评估CXCL10/CXCR3轴的作用。
主要发现
- 疾病进展中多种趋化因子显著上调,包括既往与神经退行性变相关的CXCL10。
- 微珠模型中CXCL10表达在注射后第5天明显升高。
- 第6周时,CXCR3(CXCL10的受体)缺失显著防止RGC丢失和轴突变性,且不影响眼压。
- 通过图形视网膜电图和视力评估,CXCR3缺失小鼠的视觉功能得以保留。
- 机制上,CXCL10/CXCR3信号上调星形胶质细胞中的补体成分3(C3)和RGC中的C3a受体(C3aR),驱动毒性星形胶质细胞-RGC交互。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Glaucoma is characterized by progressive retinal ganglion cell (RGC) death and optic nerve degeneration. Chemokines are a family of small, secreted proteins that mediate cell-cell communication, an essential process for maintaining microenvironmental homeostasis and regulating pathophysiological changes in multicellular organisms. However, the contribution of retina-derived chemokines to RGC loss in glaucoma remains poorly understood. METHODS: We reanalyzed a publicly available retinal bulk RNA sequencing dataset from a mouse model of glaucoma to identify differentially expressed chemokines. A mouse model of microbead-induced glaucoma and primary RGCs and astrocytes were used to assess the role of the C-X-C motif chemokine ligand 10 (CXCL10)/C-X-C motif chemokine receptor 3 (CXCR3) axis in disease. RESULTS: Several chemokines were significantly upregulated during disease progression, including CXCL10, previously implicated in neurodegeneration. In the microbead model, CXCL10 expression increased markedly by day 5 post-injection. At 6 weeks, deletion of CXCR3, the receptor for CXCL10, significantly prevented RGC loss and axonal degeneration without affecting intraocular pressure (IOP). Visual function, assessed by pattern electroretinography and visual acuity, was preserved in CXCR3-deficient mice. Mechanistically, CXCL10/CXCR3 signaling upregulated complement component 3 (C3) in astrocytes and C3a receptor (C3aR) in RGCs, driving toxic astrocyte-RGC crosstalk. Gene therapy using intravitreal injection of adeno-associated virus-mediated dominant-negative CXCL10 or pharmacological blockade of C3aR effectively reduced RGC loss. CONCLUSIONS: CXCL10/CXCR3 signaling is a key mediator of RGC loss in glaucoma. Targeting this pathway, along with its upregulated C3/C3aR axis, represents a promising IOP-independent therapeutic strategy for glaucoma.
引用
- Xia F, Shi S, Palacios E, et al. CXCR3 Deficiency Alleviates Retinal Ganglion Cell Loss by Regulating Neuron-Astrocyte Communication in a Mouse Model of Glaucoma. Invest Ophthalmol Vis Sci. 2025. PMID: 41247127. doi:10.1167/iovs.66.14.42
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。